-Reuters
ObsEva Approved On December 8, 2022 An Increase Of Its Share Capital Through The Issuance Of 20M Newly Registered Shares At An Issue Price Of 1/13 Of A Swiss Franc Each
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company